Next Article in Journal
Modelling the Effect of Process Parameters on the Wet Extrusion and Spheronisation of High-Loaded Nicotinamide Pellets Using a Quality by Design Approach
Next Article in Special Issue
Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections
Previous Article in Journal
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
Previous Article in Special Issue
Investigation of the Quantity of Exhaled Aerosols Released into the Environment during Nebulisation
Open AccessArticle

Simulation of Airway Deposition of an Aerosol Drug in COPD Patients

1
Centre for Energy Research, Hungarian Academy of Sciences, Konkoly-Thege M. út 29-33, 1121 Budapest, Hungary
2
Energy Institute, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic
3
Chiesi Hungary Ltd., Dunavirág u. 2, 1138 Budapest, Hungary
4
Department of Pulmonology, County Institute of Pulmonology, 2045 Törökbálint, Hungary
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(4), 153; https://doi.org/10.3390/pharmaceutics11040153
Received: 22 February 2019 / Revised: 21 March 2019 / Accepted: 28 March 2019 / Published: 1 April 2019
(This article belongs to the Special Issue Advances in Pulmonary Drug Delivery)
Medical aerosols are key elements of current chronic obstructive pulmonary disease (COPD) therapy. Therapeutic effects are conditioned by the delivery of the right amount of medication to the right place within the airways, that is, to the drug receptors. Deposition of the inhaled drugs is sensitive to the breathing pattern of the patients which is also connected with the patient’s disease severity. The objective of this work was to measure the realistic inhalation profiles of mild, moderate, and severe COPD patients, simulate the deposition patterns of Symbicort® Turbuhaler® dry powder drug and compare them to similar patterns of healthy control subjects. For this purpose, a stochastic airway deposition model has been applied. Our results revealed that the amount of drug depositing within the lungs correlated with the degree of disease severity. While drug deposition fraction in the lungs of mild COPD patients compared with that of healthy subjects (28% versus 31%), lung deposition fraction characteristic of severe COPD patients was lower by a factor of almost two (about 17%). Deposition fraction of moderate COPD patients was in-between (23%). This implies that for the same inhaler dosage severe COPD patients receive a significantly lower lung dose, although, they would need more. View Full-Text
Keywords: aerosol drug deposition; inhalation profile measurements; dry powder inhalers aerosol drug deposition; inhalation profile measurements; dry powder inhalers
Show Figures

Figure 1

MDPI and ACS Style

Farkas, Á.; Lizal, F.; Jedelsky, J.; Elcner, J.; Horváth, A.; Jicha, M. Simulation of Airway Deposition of an Aerosol Drug in COPD Patients. Pharmaceutics 2019, 11, 153.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop